share_log

Are Robust Financials Driving The Recent Rally In Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Stock?

Are Robust Financials Driving The Recent Rally In Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Stock?

強勁的財務狀況是否推動了愛爾眼科醫院集團有限公司(SZSE:300015)股票最近的上漲?
Simply Wall St ·  2022/06/13 23:29

Aier Eye Hospital Group (SZSE:300015) has had a great run on the share market with its stock up by a significant 37% over the last three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Specifically, we decided to study Aier Eye Hospital Group's ROE in this article.

愛爾眼科醫院集團(深圳證券交易所股票代碼:300015)在過去三個月中股價大幅上漲了37%。鑑於該公司令人印象深刻的業績,我們決定更仔細地研究其財務指標,因為公司的長期財務健康狀況通常決定着市場結果。具體地説,我們決定在本文中研究愛爾眼科醫院集團的淨資產收益率。

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

淨資產收益率,即股本回報率,是評估一家公司從股東那裏獲得投資回報的有效程度的有用工具。簡而言之,它衡量的是一家公司相對於股東權益的盈利能力。

View our latest analysis for Aier Eye Hospital Group

查看我們對愛爾眼科醫院集團的最新分析

How Do You Calculate Return On Equity?

你如何計算股本回報率?

ROE can be calculated by using the formula:

可使用以下公式計算淨資產收益率:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率=(持續經營的)淨利潤?股東權益

So, based on the above formula, the ROE for Aier Eye Hospital Group is:

因此,根據上述公式,愛爾眼科醫院集團的淨資產收益率為:

20% = CN¥2.6b ÷ CN¥13b (Based on the trailing twelve months to March 2022).

20%=26億元×130億元(以截至2022年3月的12個月為基礎)。

The 'return' is the income the business earned over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.20 in profit.

“回報”指的是企業在過去一年中獲得的收入。這意味着,股東權益每增加1元,公司就會產生0.20元的利潤。

What Has ROE Got To Do With Earnings Growth?

淨資產收益率與盈利增長有什麼關係?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

我們已經證實,淨資產收益率是一家公司未來收益的有效盈利指標。根據公司將這些利潤再投資或“保留”多少,以及這樣做的效率如何,我們就能夠評估一家公司的收益增長潛力。假設其他條件相同,與沒有相同特徵的公司相比,擁有更高股本回報率和更高利潤保留率的公司通常會有更高的增長率。

Aier Eye Hospital Group's Earnings Growth And 20% ROE

愛爾眼科醫院集團盈利增長和20%的淨資產收益率

At first glance, Aier Eye Hospital Group seems to have a decent ROE. Further, the company's ROE compares quite favorably to the industry average of 10%. This certainly adds some context to Aier Eye Hospital Group's exceptional 27% net income growth seen over the past five years. We believe that there might also be other aspects that are positively influencing the company's earnings growth. For instance, the company has a low payout ratio or is being managed efficiently.

乍一看,愛爾眼科醫院集團似乎擁有不錯的淨資產收益率。此外,該公司的淨資產收益率(ROE)與行業平均水平10%相比相當有利。這無疑為愛爾眼科醫院集團在過去五年中實現了27%的非凡淨收入增長增添了一些背景。我們認為,可能還有其他方面正在積極影響公司的收益增長。例如,該公司的派息率較低或管理效率較高。

We then compared Aier Eye Hospital Group's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 11% in the same period.

然後,我們將愛爾眼科醫院集團的淨收入增長與行業進行了比較,我們很高興地看到,與同期11%的行業增長率相比,該公司的增長數字更高。

SZSE:300015 Past Earnings Growth June 14th 2022
深圳證交所:過去300015的收益增長2022年6月14日

Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. Has the market priced in the future outlook for 300015? You can find out in our latest intrinsic value infographic research report.

盈利增長是評估一隻股票時需要考慮的一個重要指標。對於投資者來説,重要的是知道市場是否已經消化了公司預期的收益增長(或下降)。這有助於他們確定這隻股票是為光明還是黯淡的未來做準備。市場是否已經消化了300015的未來前景?你可以在我們最新的內在價值信息圖研究報告中找到答案。

Is Aier Eye Hospital Group Using Its Retained Earnings Effectively?

愛爾眼科醫院集團是否有效利用其留存收益?

Aier Eye Hospital Group's three-year median payout ratio is a pretty moderate 34%, meaning the company retains 66% of its income. This suggests that its dividend is well covered, and given the high growth we discussed above, it looks like Aier Eye Hospital Group is reinvesting its earnings efficiently.

AIER眼科醫院集團的三年平均派息率為34%,相當適中,這意味着該公司保留了66%的收入。這表明它的股息得到了很好的覆蓋,考慮到我們上面討論的高增長,看起來愛爾眼科醫院集團正在有效地對其收益進行再投資。

Moreover, Aier Eye Hospital Group is determined to keep sharing its profits with shareholders which we infer from its long history of paying a dividend for at least ten years. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 32%. Still, forecasts suggest that Aier Eye Hospital Group's future ROE will rise to 25% even though the the company's payout ratio is not expected to change by much.

此外,愛爾眼科醫院集團決心繼續與股東分享利潤,這是我們從其至少十年來支付股息的長期歷史中推斷出來的。我們最新的分析師數據顯示,該公司未來三年的派息率預計約為32%。儘管如此,預測顯示,愛爾眼科醫院集團未來的淨資產收益率將升至25%,儘管該公司的派息率預計不會有太大變化。

Conclusion

結論

In total, we are pretty happy with Aier Eye Hospital Group's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

總體而言,我們對愛爾眼科醫院集團的表現相當滿意。特別是,我們喜歡該公司對其業務進行大量再投資,並以高回報率進行投資。不出所料,這導致了令人印象深刻的收益增長。最新的行業分析師預測顯示,該公司有望保持目前的增長速度。要了解更多分析師對該公司的最新預測,請查看分析師對該公司預測的可視化。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論